Skip to main content

Table 2 Comparison of patients group with pelvic lymph node surgery

From: Role of pelvic and para-aortic lymphadenectomy in abandoned radical hysterectomy in cervical cancer

  Tumor removal and/or pelvic biopsy
N = 19 (57.6%)
Pelvic lymphadenectomy
N = 14 (42.4%)
p
Countrya
 Mexico (INCan) 10 (52.6) 2 (14.3) 0.02
 Colombia (ICLA) 9 (47.4) 12 (85.7)
Age (years)b 45 (35-53) 45.5 (40-54.3) 0.55
BMI b 27.4 (25.3–31.1) 24.6 (22.4–25.4) 0.01
Histologya
 Squamous 9 (47.4) 9 (64.3) 0.22
 Adenocarcinoma 5 (26.3) 5 (35.7)
 Adenosquamous 3 (15.8) 0
 Others 2 (10.5) 0
Initial clinical stagea
 IB1 18 (94.7) 13 (92.9) 0.82
 IB2 1 (5.3) 1 (7.1)
Tumor size (cm)b 3 (1.6–4) 3 (2–4) 0.63
Tumor gradea
 Well-differentiated 4 (21.1) 7 (50) 0.05
 Moderately differentiated 7 (36.8) 6 (42.9)
 Poorly differentiated 8 (42.1) 1 (7.1)
LVSIa 3 (15.8) 2 (14.3) 0.74
Systematic PALa 1 (5.3) 5 (35.7) 0.062
BPRa 11 (57.9) 3 (21.4) 0.073
PR positive 17 (89.5) 12 (85.7) NS
Surgical time (min)b 150 (120–190) 165 (103.8–198.8) 0.69
Blood loss (mm)b 100 (70–250) 100 (57.5–212.5) 0.78
Blood transfusiona 1 (0.05) 1 (0.07) 0.82
Others complicationsa 1 (0.05) 1 (0.07) 0.82
Hospital stay (days)b 2 (2–2) 2 (2–3.3) 0.19
Neoadjuvant treatment term (weeks)b 10 (7.5–14) 8.8 (8.1–11) 0.57
Recurrencea 7 (26.8) 2 (14.3) 0.15
 Local 1 (14.3) 0  
 Regional 6 (85.7) 2 (100)  
 Distance 0 0  
  1. Confidence interval 95%
  2. BMI body mass index, Mod moderate, LVSI lymphovascular space involvement, PAL para-aortic lymphadenectomy, BPR biopsy or pelvic lymph node removal, PR pathology report, NS not significant
  3. a N (relative frequency)
  4. bMedian (interquartile range)